{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:17:29Z","timestamp":1791580649277,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41375-024-02315-6","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:02:29Z","timestamp":1718949749000},"page":"1853-1857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone marrow transplantation reduces FGF-23 levels and restores bone formation in myelodysplastic neoplasms"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6045-3349","authenticated-orcid":false,"given":"Heike","family":"Weidner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Baschant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Ledesma-Colunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6367-8189","authenticated-orcid":false,"given":"Karolina","family":"Basiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-7299","authenticated-orcid":false,"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina S.","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4680-2071","authenticated-orcid":false,"given":"Jennifer","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-6799","authenticated-orcid":false,"given":"Martina","family":"Rauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"2315_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-0-387-78580-6_1","volume":"144","author":"S Giralt","year":"2009","unstructured":"Giralt S, Bishop MR. Principles and overview of allogeneic hematopoietic stem cell transplantation. Cancer Treat Res. 2009;144:1\u201321.","journal-title":"Cancer Treat Res"},{"key":"2315_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/leu.2017.7","volume":"31","author":"H Weidner","year":"2017","unstructured":"Weidner H, Rauner M, Trautmann F, Schmitt J, Balaian E, Mies A, et al. Myelodysplastic syndromes and bone loss in mice and men. Leukemia. 2017;31:1003\u20137.","journal-title":"Leukemia"},{"key":"2315_CR3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.137062","volume":"5","author":"H Weidner","year":"2020","unstructured":"Weidner H, Baschant U, Lademann F, Ledesma Colunga MG, Balaian E, Hofbauer C, et al. Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight. 2020;5:e137062.","journal-title":"JCI Insight"},{"key":"2315_CR4","doi-asserted-by":"publisher","first-page":"37419","DOI":"10.1074\/jbc.M304544200","volume":"278","author":"S Liu","year":"2003","unstructured":"Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278:37419\u201326.","journal-title":"J Biol Chem"},{"key":"2315_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/164_2019_330","volume":"262","author":"S Fukumoto","year":"2020","unstructured":"Fukumoto S. FGF23 and bone and mineral metabolism. Handb Exp Pharm. 2020;262:281\u2013308.","journal-title":"Handb Exp Pharm"},{"key":"2315_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.588096","volume":"12","author":"DMA Ratsma","year":"2021","unstructured":"Ratsma DMA, Zillikens MC, van der Eerden BCJ. Upstream regulators of fibroblast growth factor 23. Front Endocrinol. 2021;12:588096.","journal-title":"Front Endocrinol"},{"key":"2315_CR7","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.3390\/ijms22158039","volume":"22","author":"I Palma-Lara","year":"2021","unstructured":"Palma-Lara I, P\u00e9rez-Ram\u00edrez M, Alonso-Themann PG, Espinosa-Garc\u00eda AM, Godinez-Aguilar R, Bonilla-Delgado J, et al. FAM20C overview: classic and novel targets, pathogenic variants and raine syndrome phenotypes. Int J Mol Sci. 2021;22:8039.","journal-title":"Int J Mol Sci"},{"key":"2315_CR8","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/bloodadvances.2020001595","volume":"4","author":"AJ Van Vuren","year":"2020","unstructured":"Van Vuren AJ, Eisenga MF, Van Straaten S, Glenth\u00f8j A, Gaillard CAJM, Bakker SJL, et al. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Adv. 2020;4:1678\u201382.","journal-title":"Blood Adv"},{"key":"2315_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","volume":"16","author":"D Edmonston","year":"2020","unstructured":"Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020;16:7\u201319.","journal-title":"Nat Rev Nephrol"},{"key":"2315_CR10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2023-174273","volume":"142","author":"G Courbon","year":"2023","unstructured":"Courbon G, Thomas JJ, Martinez Calle M, Wang X, Spindler J, Von Drasek J, et al. Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation. Blood. 2023;142:106\u201318.","journal-title":"Blood"},{"key":"2315_CR11","first-page":"392","volume":"9","author":"L Lyle","year":"2018","unstructured":"Lyle L, Hirose A. Iron overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment. J Adv Pr Oncol. 2018;9:392\u2013405.","journal-title":"J Adv Pr Oncol"},{"key":"2315_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","volume":"133","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133:1039\u201348.","journal-title":"Blood"},{"key":"2315_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood-2004-12-4794","volume":"106","author":"Ywei Lin","year":"2005","unstructured":"Lin Ywei, Slape C, Zhang Z, Aplan PD. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood. 2005;106:287\u201395.","journal-title":"Blood"},{"key":"2315_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84190-0","volume":"11","author":"FT Dao","year":"2021","unstructured":"Dao FT, Wang J, Yang L, Qin YZ. Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia. Sci Rep. 2021;11:4856.","journal-title":"Sci Rep."},{"key":"2315_CR15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211872","volume":"218","author":"PG Kim","year":"2021","unstructured":"Kim PG, Niroula A, Shkolnik V, McConkey M, Lin A, S\u0142abicki M, et al. Dnmt3a -mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021;218:e20211872.","journal-title":"J Exp Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02315-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T15:02:33Z","timestamp":1722265353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02315-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02315-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ET reports honoraria for lectures and advisory boards from Amgen, UCB, Alexion, and Ascendis, and educational grants from Ascendis and UCB. KS received honoraria for lectures and advisory boards from BMS, Novartis, GSK, Jazz, and AbbVie. KSG received honoraria from BMS, AbbVie, Servier, and Amgen. UP has received honoraria from Novartis, BMS, Amgen, and Curis. LCH received support for clinical trials to his institution from Alexion, Amolyt, and Ascendis. MR received honoraria from UCB and Santhera. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}